{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T06:26:14Z","timestamp":1794810374331,"version":"4.9.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ischemic heart disease, driven largely by myocardial infarction (MI), remains the leading cause of mortality and morbidity. Although early suppression of post-MI inflammation improves outcomes, current therapies have limited efficacy. Here we show that the cellular inhibitor of apoptosis 2 (cIAP2), a regulator of cell death, is upregulated after MI and promotes acute inflammation and cardiac injury. Global deletion of cIAP2, or its loss through bone marrow transfer, reduced inflammatory injury and cardiac dysfunction after MI, indicating that the cardioprotective effect of cIAP2 deficiency is primarily mediated by the hematopoietic compartment. Reduced cardiac inflammation was associated with decreased splenic myeloid cell numbers due to increased cell death and elevated expression of the death-inducing factors TRAIL and TRAIL-R2\/DR5. Pharmacologic degradation of cIAP proteins after MI using Smac mimetics similarly reduced cardiac inflammation and protected against injury. Together, these findings identify cIAP2 as a key hematopoietic cell-expressed regulator of survival and inflammation and support its inhibition as a potential immunotherapeutic strategy for MI.<\/jats:p>","DOI":"10.1038\/s44161-026-00782-x","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:01:46Z","timestamp":1773309706000},"page":"246-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hematopoietic expression of cIAP2 drives inflammation and heart failure after myocardial infarction"],"prefix":"10.1038","volume":"5","author":[{"given":"David","family":"Smyth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7498-6496","authenticated-orcid":false,"given":"Liyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Al-Khalaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Robichaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Geoffrion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Parlow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8489-742X","authenticated-orcid":false,"given":"Feng","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McNeill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiujiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Beauregard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mireille","family":"Ouimet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9991-3306","authenticated-orcid":false,"given":"Shawn T.","family":"Beug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric C.","family":"LaCasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6230-426X","authenticated-orcid":false,"given":"Katey J.","family":"Rayner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak W.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0906-1363","authenticated-orcid":false,"given":"Benjamin","family":"Hibbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Korneluk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3017-1199","authenticated-orcid":false,"given":"Peter P.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"782_CR1","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","volume":"149","author":"SS Martin","year":"2024","unstructured":"Martin, S. S. et al. 2024 Heart Disease and Stroke Statistics: a report of US and global data from the American Heart Association. Circulation 149, e347\u2013e913 (2024).","journal-title":"Circulation"},{"key":"782_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.amjcard.2018.03.005","volume":"122","author":"J Wellings","year":"2018","unstructured":"Wellings, J., Kostis, J. B., Sargsyan, D., Cabrera, J. & Kostis, W. J. Risk factors and trends in incidence of heart failure following acute myocardial infarction. Am. J. Cardiol. 122, 1\u20135 (2018).","journal-title":"Am. J. Cardiol."},{"key":"782_CR3","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/CIRCRESAHA.111.243162","volume":"110","author":"NG Frangogiannis","year":"2012","unstructured":"Frangogiannis, N. G. Regulation of the inflammatory response in cardiac repair. Circ. Res. 110, 159\u2013173 (2012).","journal-title":"Circ. Res."},{"key":"782_CR4","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/cvr\/cvz050","volume":"115","author":"I Andreadou","year":"2019","unstructured":"Andreadou, I. et al. Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovasc. Res. 115, 1117\u20131130 (2019).","journal-title":"Cardiovasc. Res."},{"key":"782_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41577-018-0065-8","volume":"18","author":"FK Swirski","year":"2018","unstructured":"Swirski, F. K. & Nahrendorf, M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat. Rev. Immunol. 18, 733\u2013744 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"782_CR6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119\u20131131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"782_CR7","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","volume":"77","author":"K Broch","year":"2021","unstructured":"Broch, K. et al. Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction. J. Am. Coll. Cardiol. 77, 1845\u20131855 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"782_CR8","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif, J.-C. et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N. Engl. J. Med. 381, 2497\u20132505 (2019).","journal-title":"N. Engl. J. Med."},{"key":"782_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nri3800","volume":"15","author":"S Epelman","year":"2015","unstructured":"Epelman, S., Liu, P. P. & Mann, D. L. Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat. Rev. Immunol. 15, 117\u2013129 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"782_CR10","doi-asserted-by":"publisher","first-page":"a006049","DOI":"10.1101\/cshperspect.a006049","volume":"4","author":"K Newton","year":"2012","unstructured":"Newton, K. & Dixit, V. M. Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 4, a006049 (2012).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"782_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.jacbts.2020.03.015","volume":"5","author":"RI Ja\u00e9n","year":"2020","unstructured":"Ja\u00e9n, R. I. et al. Innate immune receptors, key actors in cardiovascular diseases. JACC Basic Transl. Sci. 5, 735\u2013749 (2020).","journal-title":"JACC Basic Transl. Sci."},{"key":"782_CR12","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1161\/01.CIR.0000147233.10318.23","volume":"110","author":"M Sun","year":"2004","unstructured":"Sun, M. et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation 110, 3221\u20133228 (2004).","journal-title":"Circulation"},{"key":"782_CR13","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1161\/CIRCULATIONAHA.109.865956","volume":"120","author":"Y Maekawa","year":"2009","unstructured":"Maekawa, Y. et al. Survival and cardiac remodeling after myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-associated kinase-4 signaling. Circulation 120, 1401\u20131414 (2009).","journal-title":"Circulation"},{"key":"782_CR14","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1016\/j.yjmcc.2010.02.020","volume":"48","author":"R Fallach","year":"2010","unstructured":"Fallach, R. et al. Cardiomyocyte Toll-like receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. J. Mol. Cell. Cardiol. 48, 1236\u20131244 (2010).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"782_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00335-005-0120-1","volume":"17","author":"MH Harpster","year":"2006","unstructured":"Harpster, M. H. et al. Earliest changes in the left ventricular transcriptome post-myocardial infarction. Mamm. Genome 17, 701\u2013715 (2006).","journal-title":"Mamm. Genome"},{"key":"782_CR16","doi-asserted-by":"crossref","unstructured":"Lalaoui, N. & Vaux, D. L. Recent advances in understanding inhibitor of apoptosis proteins. F1000Res. 7, F1000 Faculty Rev-1889 (2018).","DOI":"10.12688\/f1000research.16439.1"},{"key":"782_CR17","doi-asserted-by":"publisher","first-page":"a008730","DOI":"10.1101\/cshperspect.a008730","volume":"5","author":"J Silke","year":"2013","unstructured":"Silke, J. & Meier, P. Inhibitor of apoptosis (IAP) proteins\u2014modulators of cell death and inflammation. Cold Spring Harb. Perspect. Biol. 5, a008730 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"782_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aax8295","volume":"13","author":"S Jensen","year":"2020","unstructured":"Jensen, S., Seidelin, J. B., LaCasse, E. C. & Nielsen, O. H. SMAC mimetics and RIPK inhibitors as therapeutics for chronic inflammatory diseases. Sci. Signal. 13, eaax8295 (2020).","journal-title":"Sci. Signal."},{"key":"782_CR19","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/0092-8674(95)90149-3","volume":"83","author":"M Rothe","year":"1995","unstructured":"Rothe, M., Pan, M.-G., Henzel, W. J., Ayres, T. M. & Goeddel, D. V. The TNFR2\u2212TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 83, 1243\u20131252 (1995).","journal-title":"Cell"},{"key":"782_CR20","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.tcb.2016.01.006","volume":"26","author":"N Peltzer","year":"2016","unstructured":"Peltzer, N., Darding, M. & Walczak, H. Holding RIPK1 on the ubiquitin leash in TNFR1 signaling. Trends Cell Biol. 26, 445\u2013461 (2016).","journal-title":"Trends Cell Biol."},{"key":"782_CR21","doi-asserted-by":"publisher","first-page":"ra22","DOI":"10.1126\/scisignal.2001878","volume":"5","author":"E Varfolomeev","year":"2012","unstructured":"Varfolomeev, E. et al. Cellular inhibitors of apoptosis are global regulators of NF-\u03baB and MAPK activation by members of the TNF family of receptors. Sci. Signal. 5, ra22 (2012).","journal-title":"Sci. Signal."},{"key":"782_CR22","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/ni.1676","volume":"9","author":"BJ Zarnegar","year":"2008","unstructured":"Zarnegar, B. J. et al. Noncanonical NF-\u03baB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 9, 1371\u20131378 (2008).","journal-title":"Nat. Immunol."},{"key":"782_CR23","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/ni.1678","volume":"9","author":"S Vallabhapurapu","year":"2008","unstructured":"Vallabhapurapu, S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-\u03baB signaling. Nat. Immunol. 9, 1364\u20131370 (2008).","journal-title":"Nat. Immunol."},{"key":"782_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/ni.1819","volume":"11","author":"P-H Tseng","year":"2010","unstructured":"Tseng, P.-H. et al. Different modes of ubiquitination of the adaptor TRAF3 selectively activate the expression of type I interferons and proinflammatory cytokines. Nat. Immunol. 11, 70\u201375 (2010).","journal-title":"Nat. Immunol."},{"key":"782_CR25","doi-asserted-by":"publisher","first-page":"ra35","DOI":"10.1126\/scisignal.2003708","volume":"6","author":"B Zhong","year":"2013","unstructured":"Zhong, B. et al. Ubiquitin-specific protease 25 regulates TLR4-dependent innate immune responses through deubiquitination of the adaptor protein TRAF3. Science Signaling 6, ra35 (2013).","journal-title":"Science Signaling"},{"key":"782_CR26","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s10495-007-0087-3","volume":"12","author":"AM Hunter","year":"2007","unstructured":"Hunter, A. M., LaCasse, E. C. & Korneluk, R. G. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12, 1543\u20131568 (2007).","journal-title":"Apoptosis"},{"key":"782_CR27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1128\/MCB.26.2.699-708.2006","volume":"26","author":"D Conte","year":"2006","unstructured":"Conte, D. et al. Inhibitor of apoptosis protein cIAP2 is essential for lipopolysaccharide-induced macrophage survival. Mol. Cell. Biol. 26, 699\u2013708 (2006).","journal-title":"Mol. Cell. Biol."},{"key":"782_CR28","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0092-8674(00)00008-8","volume":"102","author":"C Du","year":"2000","unstructured":"Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that promotes cytochrome c\u2013dependent caspase activation by eliminating IAP inhibition. Cell 102, 33\u201342 (2000).","journal-title":"Cell"},{"key":"782_CR29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nbt.2806","volume":"32","author":"ST Beug","year":"2014","unstructured":"Beug, S. T. et al. Smac mimetics and innate immune stimuli synergize to promote tumor death. Nat. Biotechnol. 32, 182\u2013190 (2014).","journal-title":"Nat. Biotechnol."},{"key":"782_CR30","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1038\/nm.4229","volume":"22","author":"M Chesi","year":"2016","unstructured":"Chesi, M. et al. IAP antagonists induce anti-tumor immunity in multiple myeloma. Nat. Med. 22, 1411\u20131420 (2016).","journal-title":"Nat. Med."},{"key":"782_CR31","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13046-016-0435-7","volume":"35","author":"C Yang","year":"2016","unstructured":"Yang, C. et al. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC. J. Exp. Clin. Cancer Res. 35, 158 (2016).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"782_CR32","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1182\/bloodadvances.2020003829","volume":"5","author":"N Pemmaraju","year":"2021","unstructured":"Pemmaraju, N. et al. Final results of a phase 2 clinical trial of LCL161, an oral SMAC mimetic for patients with myelofibrosis. Blood Adv. 5, 3163\u20133173 (2021).","journal-title":"Blood Adv."},{"key":"782_CR33","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1128\/MCB.25.8.3348-3356.2005","volume":"25","author":"DB Conze","year":"2005","unstructured":"Conze, D. B. et al. Posttranscriptional downregulation of c-IAP2 by the ubiquitin protein ligase c-IAP1 in vivo. Mol. Cell. Biol. 25, 3348\u20133356 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"782_CR34","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.112.004408","volume":"1","author":"X Yan","year":"2012","unstructured":"Yan, X. et al. Deleterious effect of the IL-23\/IL-17A axis and \u03b3\u03b4T cells on left ventricular remodeling after myocardial infarction. J. Am. Heart Assoc. 1, e004408 (2012).","journal-title":"J. Am. Heart Assoc."},{"key":"782_CR35","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1161\/CIRCRESAHA.113.301720","volume":"114","author":"MA Ismahil","year":"2014","unstructured":"Ismahil, M. A. et al. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure. Circ. Res. 114, 266\u2013282 (2014).","journal-title":"Circ. Res."},{"key":"782_CR36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1084\/jem.20111009","volume":"209","author":"F Leuschner","year":"2012","unstructured":"Leuschner, F. et al. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J. Exp. Med. 209, 123\u2013137 (2012).","journal-title":"J. Exp. Med."},{"key":"782_CR37","doi-asserted-by":"publisher","first-page":"e1800","DOI":"10.1038\/cddis.2015.158","volume":"6","author":"MC de Almagro","year":"2015","unstructured":"de Almagro, M. C., Goncharov, T., Newton, K. & Vucic, D. Cellular IAP proteins and LUBAC differentially regulate necrosome-associated RIP1 ubiquitination. Cell Death Dis. 6, e1800 (2015).","journal-title":"Cell Death Dis."},{"key":"782_CR38","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1038\/cdd.2012.59","volume":"19","author":"S McComb","year":"2012","unstructured":"McComb, S. et al. cIAP1 and cIAP2 limit macrophage necroptosis by inhibiting Rip1 and Rip3 activation. Cell Death Differ. 19, 1791\u20131801 (2012).","journal-title":"Cell Death Differ."},{"key":"782_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.stem.2019.05.019","volume":"25","author":"M Yamashita","year":"2019","unstructured":"Yamashita, M. & Passegu\u00e9, E. TNF-\u03b1 coordinates hematopoietic stem cell survival and myeloid regeneration. Cell Stem Cell 25, 357\u2013372 (2019).","journal-title":"Cell Stem Cell"},{"key":"782_CR40","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1038\/sj.emboj.7600302","volume":"23","author":"N Clarke","year":"2004","unstructured":"Clarke, N., Jimenez-Lara, A. M., Voltz, E. & Gronemeyer, H. Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J. 23, 3051\u20133060 (2004).","journal-title":"EMBO J."},{"key":"782_CR41","doi-asserted-by":"publisher","first-page":"3103","DOI":"10.1200\/JCO.2013.52.3993","volume":"32","author":"JR Infante","year":"2014","unstructured":"Infante, J. R. et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 32, 3103\u20133110 (2014).","journal-title":"J. Clin. Oncol."},{"key":"782_CR42","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1161\/CIRCULATIONAHA.112.113811","volume":"126","author":"ST Nauta","year":"2012","unstructured":"Nauta, S. T., Deckers, J. W., van Domburg, R. T. & Akkerhuis, K. M. Sex-related trends in mortality in hospitalized men and women after myocardial infarction between 1985 and 2008. Circulation 126, 2184\u20132189 (2012).","journal-title":"Circulation"},{"key":"782_CR43","first-page":"46","volume":"3","author":"ES Ketchum","year":"2014","unstructured":"Ketchum, E. S. et al. The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction. Eur. Heart J. Acute Cardiovasc. Care 3, 46\u201355 (2014).","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"782_CR44","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/CIRCULATIONAHA.120.047065","volume":"143","author":"SAE Peters","year":"2021","unstructured":"Peters, S. A. E. et al. Trends in recurrent coronary heart disease after myocardial infarction among US women and men between 2008 and 2017. Circulation 143, 650\u2013660 (2021).","journal-title":"Circulation"},{"key":"782_CR45","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000021288","volume":"99","author":"Q Ye","year":"2020","unstructured":"Ye, Q., Zhang, J. & Ma, L. Predictors of all-cause 1-year mortality in myocardial infarction patients. Medicine 99, e21288 (2020).","journal-title":"Medicine"},{"key":"782_CR46","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1177\/2047487317698568","volume":"24","author":"G Sulo","year":"2017","unstructured":"Sulo, G. et al. Trends in the risk of early and late-onset heart failure as an adverse outcome of acute myocardial infarction: a Cardiovascular Disease in Norway project. Eur. J. Prev. Cardiol. 24, 971\u2013980 (2017).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"782_CR47","doi-asserted-by":"publisher","first-page":"e001499","DOI":"10.1136\/openhrt-2020-001499","volume":"8","author":"S Pocock","year":"2021","unstructured":"Pocock, S. et al. Health-related quality of life 1\u20133 years post-myocardial infarction: its impact on prognosis. Open Heart 8, e001499 (2021).","journal-title":"Open Heart"},{"key":"782_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood-2004-05-1831","volume":"105","author":"M Massa","year":"2005","unstructured":"Massa, M. et al. Increased circulating hematopoietic and endothelial progenitor cells in the early phase of acute myocardial infarction. Blood 105, 199\u2013206 (2005).","journal-title":"Blood"},{"key":"782_CR49","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ahj.2011.09.002","volume":"163","author":"AM van der Laan","year":"2012","unstructured":"van der Laan, A. M. et al. A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: monocytes and myocardial infarction. Am. Heart J. 163, 57\u201365 (2012).","journal-title":"Am. Heart J."},{"key":"782_CR50","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12265-017-9782-9","volume":"11","author":"S Zeng","year":"2018","unstructured":"Zeng, S. et al. Trajectories of circulating monocyte subsets after ST-elevation myocardial infarction during hospitalization: latent class growth modeling for high-risk patient identification. J. Cardiovasc. Trans. Res. 11, 22\u201332 (2018).","journal-title":"J. Cardiovasc. Trans. Res."},{"key":"782_CR51","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.amjcard.2008.09.085","volume":"103","author":"S Chia","year":"2009","unstructured":"Chia, S. et al. Association of leukocyte and neutrophil counts with infarct size, left ventricular function and outcomes after percutaneous coronary intervention for ST-elevation myocardial infarction. Am. J. Cardiol. 103, 333\u2013337 (2009).","journal-title":"Am. J. Cardiol."},{"key":"782_CR52","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.immuni.2009.04.011","volume":"30","author":"MJM Bertrand","year":"2009","unstructured":"Bertrand, M. J. M. et al. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 30, 789\u2013801 (2009).","journal-title":"Immunity"},{"key":"782_CR53","doi-asserted-by":"publisher","first-page":"11778","DOI":"10.1073\/pnas.0711122105","volume":"105","author":"DJ Mahoney","year":"2008","unstructured":"Mahoney, D. J. et al. Both cIAP1 and cIAP2 regulate TNF\u03b1-mediated NF-\u03baB activation. Proc. Natl Acad. Sci. USA 105, 11778\u201311783 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"782_CR54","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-15-0365","volume":"21","author":"S Fulda","year":"2015","unstructured":"Fulda, S. Promises and challenges of Smac mimetics as cancer therapeutics. Clin. Cancer Res. 21, 5030\u20135036 (2015).","journal-title":"Clin. Cancer Res."},{"key":"782_CR55","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.stem.2015.04.008","volume":"16","author":"P Dutta","year":"2015","unstructured":"Dutta, P. et al. Myocardial infarction activates CCR2+ hematopoietic stem and progenitor cells. Cell Stem Cell 16, 477\u2013487 (2015).","journal-title":"Cell Stem Cell"},{"key":"782_CR56","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1126\/science.1175202","volume":"325","author":"FK Swirski","year":"2009","unstructured":"Swirski, F. K. et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325, 612\u2013616 (2009).","journal-title":"Science"},{"key":"782_CR57","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nature11260","volume":"487","author":"P Dutta","year":"2012","unstructured":"Dutta, P. et al. Myocardial infarction accelerates atherosclerosis. Nature 487, 325\u2013329 (2012).","journal-title":"Nature"},{"key":"782_CR58","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1182\/blood-2013-06-510743","volume":"123","author":"WW-L Wong","year":"2014","unstructured":"Wong, W. W.-L. et al. cIAPs and XIAP regulate myelopoiesis through cytokine production in an RIPK1- and RIPK3-dependent manner. Blood 123, 2562\u20132572 (2014).","journal-title":"Blood"},{"key":"782_CR59","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/1074-7613(95)90057-8","volume":"3","author":"SR Wiley","year":"1995","unstructured":"Wiley, S. R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673\u2013682 (1995).","journal-title":"Immunity"},{"key":"782_CR60","first-page":"2770","volume":"59","author":"GS Wu","year":"1999","unstructured":"Wu, G. S., Burns, T. F., Zhan, Y., Alnemri, E. S. & El-Deiry, W. S. Molecular cloning and functional analysis of the mouse homologue of the KILLER\/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59, 2770\u20132775 (1999).","journal-title":"Cancer Res."},{"key":"782_CR61","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1093\/eurheartj\/ehp004","volume":"30","author":"A Niessner","year":"2009","unstructured":"Niessner, A. et al. Prognostic value of apoptosis markers in advanced heart failure patients. Eur. Heart J. 30, 789\u2013796 (2009).","journal-title":"Eur. Heart J."},{"key":"782_CR62","doi-asserted-by":"publisher","first-page":"e4442","DOI":"10.1371\/journal.pone.0004442","volume":"4","author":"P Secchiero","year":"2009","unstructured":"Secchiero, P. et al. Potential prognostic significance of decreased serum levels of TRAIL after acute myocardial infarction. PLoS ONE 4, e4442 (2009).","journal-title":"PLoS ONE"},{"key":"782_CR63","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1177\/2047487317725017","volume":"24","author":"E Skau","year":"2017","unstructured":"Skau, E. et al. GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction. Eur. J. Prev. Cardiol. 24, 1576\u20131583 (2017).","journal-title":"Eur. J. Prev. Cardiol."},{"key":"782_CR64","doi-asserted-by":"crossref","unstructured":"Wang, X. et al. Blocking the TRAIL-DR5 pathway reduces cardiac ischemia\u2013reperfusion injury by decreasing neutrophil infiltration and neutrophil extracellular traps formation. Cardiovasc. Drugs Ther. 39, 983\u2212999 (2024).","DOI":"10.1007\/s10557-024-07591-z"},{"key":"782_CR65","doi-asserted-by":"publisher","first-page":"103600","DOI":"10.1016\/j.jpet.2025.103600","volume":"392","author":"MA Tanner","year":"2025","unstructured":"Tanner, M. A., Dougherty, K. & Grisanti, L. A. Death receptor 5 agonists mitigate cardiac pathology in a chronic isoproterenol-induced cardiac remodeling and dysfunction. J. Pharmacol. Exp. Ther. 392, 103600 (2025).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"782_CR66","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1084\/jem.20122235","volume":"209","author":"CA Benedict","year":"2012","unstructured":"Benedict, C. A. & Ware, C. F. TRAIL: not just for tumors anymore? J. Exp. Med. 209, 1903\u20131906 (2012).","journal-title":"J. Exp. Med."},{"key":"782_CR67","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/imr.13404","volume":"328","author":"M Hematianlarki","year":"2024","unstructured":"Hematianlarki, M. & Nimmerjahn, F. Immunomodulatory and anti-inflammatory properties of immunoglobulin G antibodies. Immunol. Rev. 328, 372\u2013386 (2024).","journal-title":"Immunol. Rev."},{"key":"782_CR68","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/35022514","volume":"406","author":"J Chai","year":"2000","unstructured":"Chai, J. et al. Structural and biochemical basis of apoptotic activation by Smac\/DIABLO. Nature 406, 855\u2013862 (2000).","journal-title":"Nature"},{"key":"782_CR69","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.pharmthera.2014.05.007","volume":"144","author":"L Bai","year":"2014","unstructured":"Bai, L., Smith, D. C. & Wang, S. Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol. Ther. 144, 82\u201395 (2014).","journal-title":"Pharmacol. Ther."},{"key":"782_CR70","doi-asserted-by":"publisher","first-page":"16963","DOI":"10.1074\/jbc.M401253200","volume":"279","author":"Q-H Yang","year":"2004","unstructured":"Yang, Q.-H. & Du, C. Smac\/DIABLO selectively reduces the levels of c-IAP1 and c-IAP2 but not that of XIAP and Livin in HeLa cells. J. Biol. Chem. 279, 16963\u201316970 (2004).","journal-title":"J. Biol. Chem."},{"key":"782_CR71","doi-asserted-by":"publisher","first-page":"26906","DOI":"10.1074\/jbc.M313859200","volume":"279","author":"EM Creagh","year":"2004","unstructured":"Creagh, E. M., Murphy, B. M., Duriez, P. J., Duckett, C. S. & Martin, S. J. Smac\/Diablo antagonizes ubiquitin ligase activity of inhibitor of apoptosis proteins. J. Biol. Chem. 279, 26906\u201326914 (2004).","journal-title":"J. Biol. Chem."},{"key":"782_CR72","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/cdd.2011.10","volume":"18","author":"M Darding","year":"2011","unstructured":"Darding, M. et al. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ. 18, 1376\u20131386 (2011).","journal-title":"Cell Death Differ."},{"key":"782_CR73","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.chom.2013.12.003","volume":"15","author":"IG Rodrigue-Gervais","year":"2014","unstructured":"Rodrigue-Gervais, I. G. et al. Cellular inhibitor of apoptosis protein cIAP2 protects against pulmonary tissue necrosis during influenza virus infection to promote host survival. Cell Host Microbe 15, 23\u201335 (2014).","journal-title":"Cell Host Microbe"},{"key":"782_CR74","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.molcel.2018.01.027","volume":"69","author":"A Annibaldi","year":"2018","unstructured":"Annibaldi, A. et al. Ubiquitin-mediated regulation of RIPK1 kinase activity independent of IKK and MK2. Mol. Cell 69, 566\u2013580 (2018).","journal-title":"Mol. Cell"},{"key":"782_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-022-02527-6","volume":"19","author":"DD Biswas","year":"2022","unstructured":"Biswas, D. D. et al. Cellular inhibitor of apoptosis 2 (cIAP2) restricts neuroinflammation during experimental autoimmune encephalomyelitis. J. Neuroinflammation 19, 158 (2022).","journal-title":"J. Neuroinflammation"},{"key":"782_CR76","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1093\/cei\/uxad092","volume":"215","author":"JB Seidelin","year":"2024","unstructured":"Seidelin, J. B. et al. IAPs and RIPK1 mediate LPS-induced cytokine production in healthy subjects and Crohn\u2019s disease. Clin. Exp. Immunol. 215, 291\u2013301 (2024).","journal-title":"Clin. Exp. Immunol."},{"key":"782_CR77","doi-asserted-by":"publisher","first-page":"101464","DOI":"10.1016\/j.trim.2021.101464","volume":"69","author":"S Li","year":"2021","unstructured":"Li, S., Yang, P., Xu, L. & Li, M. Blocking of Birc3\/TLR4\/Myd88 signaling protects carbapenem-resistant klebsiella pneumoniae in a mouse model of infection. Transplant. Immunol. 69, 101464 (2021).","journal-title":"Transplant. Immunol."},{"key":"782_CR78","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s44161-022-00181-y","volume":"1","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Insulin-like growth factor-binding protein-7 (IGFBP7) links senescence to heart failure. Nat. Cardiovasc. Res. 1, 1195\u20131214 (2022).","journal-title":"Nat. Cardiovasc. Res."},{"key":"782_CR79","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12859-018-2308-x","volume":"19","author":"ML Amaral","year":"2018","unstructured":"Amaral, M. L., Erikson, G. A. & Shokhirev, M. N. BART: bioinformatics array research tool. BMC Bioinformatics 19, 296 (2018).","journal-title":"BMC Bioinformatics"},{"key":"782_CR80","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1084\/jem.20130536","volume":"210","author":"Y-L Chen","year":"2013","unstructured":"Chen, Y.-L. et al. A type I IFN\u2013Flt3 ligand axis augments plasmacytoid dendritic cell development from common lymphoid progenitors. J. Exp. Med. 210, 2515\u20132522 (2013).","journal-title":"J. Exp. Med."},{"key":"782_CR81","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/ilar.43.4.207","volume":"43","author":"RB Dell","year":"2002","unstructured":"Dell, R. B., Holleran, S. & Ramakrishnan, R. Sample size determination. ILAR J. 43, 207\u2013213 (2002).","journal-title":"ILAR J."}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00782-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00782-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00782-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:06:11Z","timestamp":1773763571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00782-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":81,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1038\/s44161-026-00782-x","relation":{},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"5 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.C.L. is a co-founder and the Chief Scientific Officer of Protaxis Therapeutics, Inc. All other authors report no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}